Supply / Manufacturing · Latin America · Announced 17 Nov 2026

Celltrion → Brazilian federal government

Celltrion won Brazil's federal government tender for its trastuzumab biosimilar Herzuma for a seventh straight year, becoming sole supplier of about 1 million vials through end-2027.

Parties: Celltrion (South Korea) → Brazilian federal government (public tender) (Brazil)

Value
Undisclosed
Territory
Brazil — federal public-sector trastuzumab supply (about 80% of the public trastuzumab market)
Therapeutic area
Oncology
Asset
Herzuma (trastuzumab)
Announced
17 Nov 2026

Our analysis

Why this matters

Celltrion announced on 17 November 2026 that its Brazilian subsidiary won a Brazilian federal government tender for Herzuma, its biosimilar of trastuzumab used in breast and gastric cancer. Celltrion will be the sole supplier of about 1 million vials through the end of 2027. No contract value was disclosed. It is the seventh consecutive year Herzuma has won the federal tender; the first win came in 2020, the year after its Brazilian launch.

According to the company, the federal tender covers about 80% of Brazil's public trastuzumab market, and public and private channels split roughly 80/20. Celltrion cites IQVIA data putting Herzuma's share of Brazilian trastuzumab at about 50%.

The full analysis is free to read with a work email on this page.

Source: Korea Biomedical Review

More deals involving Celltrion or Brazilian federal government

Latest deals

All Latin America deals → · All supply / manufacturing deals → · Browse all emerging-market pharma deals →